News

Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint, to generate small-molecule lead compounds against undisclosed targets of therapeutic interest to Janssen. Reportedly, Janssen is

The expansion of the trial (currently ongoing in France) to two new countries will raise the total number of centers to over 40 and will help accelerate patient

CCR4 is one of 18 known chemokine receptors – proteins which bind molecules called chemokines to trigger various cellular responses. Developing antibodies to interfere with CCR4-expressing cells, such

Germany-based Huttlin produces specialist drying and granulation equipment from powder to the production of pharmaceuticals. The UK based Manesty specializes in tablet presses and coaters. Bosch Packaging Technology,

Impax, a manufacturer of both brand and generic drug products, has implemented SAP to derive the benefits of tighter integration of global processes, accelerate the adoption of best

The analysis evaluated data from two large multinational Phase III, double-blind, placebo-controlled studies (RAPID 1 and 2) comparing the efficacy and safety of certolizumab pegol plus MTX versus

The new patent entitled, ‘Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects,’ relates to step-wise increase of lomitapide doses for the

PPD has posted a net income of $37.37m, or $0.32 per diluted share, compared to $17.2m, or $0.14 per diluted share, for the same period in 2010. For

IQ Therapeutics said doses up to 7.5 mg/kg have been administered, as per protocol. IQNLF is a fully human antibody developed using IQ Therapeutics’ proprietary technology – Cloning